Reviews Ticlid


No reviews yet.

Ticlid Drug Description
TICLID®
(ticlopidine hydrochloride) Tablets

WARNING
TICLID can cause life-threatening hematological adverse reactions, including
neutropenia/agranulocytosis, thrombotic thrombocytopenic purpura (TTP) and aplastic anemia.
Neutropenia/Agranulocytosis: Among 2048 patients in clinical
trials in stroke patients, there were 50 cases (2.4%) of neutropenia (less than
1200 neutrophils/mm³), and the neutrophil count was below 450/mm³
in 17 of these patients (0.8% of the total population).
TTP: One case of thrombotic thrombocytopenic purpura was reported
during clinical trials in stroke patients. Based on postmarketing data, US physicians
reported about 100 cases between 1992 and 1997. Based on an estimated patient
exposure of 2 million to 4 million, and assuming an event reporting rate of
10% (the true rate is not known), the incidence of ticlopidine-associated TTP
may be as high as one case in every 2000 to 4000 patients exposed.
Aplastic Anemia: Aplastic anemia was not seen during clinical
trials in stroke patients, but US physicians reported about 50 cases between
1992 and 1998. Based on an estimated patient exposure of 2 million to 4 million,
and assuming an event reporting rate of 10% (the true rate is not known), the
incidence of ticlopidine-associated aplastic anemia may be as high as one case
in every 4000 to 8000 patients exposed.
Monitoring of Clinical and Hematologic Status: Severe hematological
adverse reactions may occur within a few days of the start of therapy. The incidence
of TTP peaks after about 3 to 4 weeks of therapy and neutropenia peaks at approximately
4 to 6 weeks. The incidence of aplastic anemia peaks after about 4 to 8 weeks
of therapy. The incidence of the hematologic adverse reactions declines thereafter.
Only a few cases of neutropenia, TTP, or aplastic anemia have arisen after more
than 3 months of therapy.
Hematological adverse reactions cannot be reliably predicted by any identified
demographic or clinical characteristics. During the first 3 months of treatment,
patients receiving TICLID must, therefore, be hematologically and clinically
monitored for evidence of neutropenia or TTP. If any such evidence is seen,
TICLID should be immediately discontinued.
The detection and treatment of ticlopidine-associated hematological adverse
reactions are further described under WARNINGS.

DRUG DESCRIPTION



What are the possible side effects of ticlopidine (Ticlid)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using ticlopidine and call your doctor at once if you have a serious side effect such as:

nosebleed or other bleeding that will not stop;
black, bloody, or tarry stools;
coughing up blood or vomit that looks like coffee grounds;
chest pain or heavy feeling, pain spreading to the arm or shoulder,...
Read All Potential Side Effects for Ticlid »




TICLID (ticlopidine hydrochloride) is a platelet aggregation inhibitor. Chemically
it is 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno [3,2-c] pyridine hydrochloride.
The structural formula is:








Ticlopidine hydrochloride is a white crystalline solid. It is freely soluble
in water and self-buffers to a pH of 3.6. It also dissolves freely in methanol,
is sparingly soluble in methylene chloride and ethanol, slightly soluble in
acetone and insoluble in a buffer solution of pH 6.3. It has a molecular weight
of 300.25.
TICLID tablets for oral administration are provided as white, oval, film-coated,
blue-imprinted tablets containing 250 mg of ticlopidine hydrochloride. Each
tablet also contains citric acid, magnesium stearate, microcrystalline cellulose,
povidone, starch and stearic acid as inactive ingredients. The white film-coating
contains hydroxypropylmethyl cellulose, polyethylene glycol and titanium dioxide.
Each tablet is printed with blue ink, which includes FD&C Blue #1 aluminum
lake as the colorant. The tablets are identified with Ticlid on one side and
250 on the reverse side.Last reviewed on RxList: 6/10/2008




Ticlid Drug Description
TICLID®
(ticlopidine hydrochloride) Tablets

WARNING
TICLID can cause life-threatening hematological adverse reactions, including
neutropenia/agranulocytosis, thrombotic thrombocytopenic purpura (TTP) and aplastic anemia.
Neutropenia/Agranulocytosis: Among 2048 patients in clinical
trials in stroke patients, there were 50 cases (2.4%) of neutropenia (less than
1200 neutrophils/mm³), and the neutrophil count was below 450/mm³
in 17 of these patients (0.8% of the total population).
TTP: One case of thrombotic thrombocytopenic purpura was reported
during clinical trials in stroke patients. Based on postmarketing data, US physicians
reported about 100 cases between 1992 and 1997. Based on an estimated patient
exposure of 2 million to 4 million, and assuming an event reporting rate of
10% (the true rate is not known), the incidence of ticlopidine-associated TTP
may be as high as one case in every 2000 to 4000 patients exposed.
Aplastic Anemia: Aplastic anemia was not seen during clinical
trials in stroke patients, but US physicians reported about 50 cases between
1992 and 1998. Based on an estimated patient exposure of 2 million to 4 million,
and assuming an event reporting rate of 10% (the true rate is not known), the
incidence of ticlopidine-associated aplastic anemia may be as high as one case
in every 4000 to 8000 patients exposed.
Monitoring of Clinical and Hematologic Status: Severe hematological
adverse reactions may occur within a few days of the start of therapy. The incidence
of TTP peaks after about 3 to 4 weeks of therapy and neutropenia peaks at approximately
4 to 6 weeks. The incidence of aplastic anemia peaks after about 4 to 8 weeks
of therapy. The incidence of the hematologic adverse reactions declines thereafter.
Only a few cases of neutropenia, TTP, or aplastic anemia have arisen after more
than 3 months of therapy.
Hematological adverse reactions cannot be reliably predicted by any identified
demographic or clinical characteristics. During the first 3 months of treatment,
patients receiving TICLID must, therefore, be hematologically and clinically
monitored for evidence of neutropenia or TTP. If any such evidence is seen,
TICLID should be immediately discontinued.
The detection and treatment of ticlopidine-associated hematological adverse
reactions are further described under WARNINGS.

DRUG DESCRIPTION



What are the possible side effects of ticlopidine (Ticlid)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using ticlopidine and call your doctor at once if you have a serious side effect such as:

nosebleed or other bleeding that will not stop;
black, bloody, or tarry stools;
coughing up blood or vomit that looks like coffee grounds;
chest pain or heavy feeling, pain spreading to the arm or shoulder,...
Read All Potential Side Effects for Ticlid »




TICLID (ticlopidine hydrochloride) is a platelet aggregation inhibitor. Chemically
it is 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno [3,2-c] pyridine hydrochloride.
The structural formula is:








Ticlopidine hydrochloride is a white crystalline solid. It is freely soluble
in water and self-buffers to a pH of 3.6. It also dissolves freely in methanol,
is sparingly soluble in methylene chloride and ethanol, slightly soluble in
acetone and insoluble in a buffer solution of pH 6.3. It has a molecular weight
of 300.25.
TICLID tablets for oral administration are provided as white, oval, film-coated,
blue-imprinted tablets containing 250 mg of ticlopidine hydrochloride. Each
tablet also contains citric acid, magnesium stearate, microcrystalline cellulose,
povidone, starch and stearic acid as inactive ingredients. The white film-coating
contains hydroxypropylmethyl cellulose, polyethylene glycol and titanium dioxide.
Each tablet is printed with blue ink, which includes FD&C Blue #1 aluminum
lake as the colorant. The tablets are identified with Ticlid on one side and
250 on the reverse side.Last reviewed on RxList: 6/10/2008




Ticlid Drug Description
TICLID®
(ticlopidine hydrochloride) Tablets

WARNING
TICLID can cause life-threatening hematological adverse reactions, including
neutropenia/agranulocytosis, thrombotic thrombocytopenic purpura (TTP) and aplastic anemia.
Neutropenia/Agranulocytosis: Among 2048 patients in clinical
trials in stroke patients, there were 50 cases (2.4%) of neutropenia (less than
1200 neutrophils/mm³), and the neutrophil count was below 450/mm³
in 17 of these patients (0.8% of the total population).
TTP: One case of thrombotic thrombocytopenic purpura was reported
during clinical trials in stroke patients. Based on postmarketing data, US physicians
reported about 100 cases between 1992 and 1997. Based on an estimated patient
exposure of 2 million to 4 million, and assuming an event reporting rate of
10% (the true rate is not known), the incidence of ticlopidine-associated TTP
may be as high as one case in every 2000 to 4000 patients exposed.
Aplastic Anemia: Aplastic anemia was not seen during clinical
trials in stroke patients, but US physicians reported about 50 cases between
1992 and 1998. Based on an estimated patient exposure of 2 million to 4 million,
and assuming an event reporting rate of 10% (the true rate is not known), the
incidence of ticlopidine-associated aplastic anemia may be as high as one case
in every 4000 to 8000 patients exposed.
Monitoring of Clinical and Hematologic Status: Severe hematological
adverse reactions may occur within a few days of the start of therapy. The incidence
of TTP peaks after about 3 to 4 weeks of therapy and neutropenia peaks at approximately
4 to 6 weeks. The incidence of aplastic anemia peaks after about 4 to 8 weeks
of therapy. The incidence of the hematologic adverse reactions declines thereafter.
Only a few cases of neutropenia, TTP, or aplastic anemia have arisen after more
than 3 months of therapy.
Hematological adverse reactions cannot be reliably predicted by any identified
demographic or clinical characteristics. During the first 3 months of treatment,
patients receiving TICLID must, therefore, be hematologically and clinically
monitored for evidence of neutropenia or TTP. If any such evidence is seen,
TICLID should be immediately discontinued.
The detection and treatment of ticlopidine-associated hematological adverse
reactions are further described under WARNINGS.

DRUG DESCRIPTION



What are the possible side effects of ticlopidine (Ticlid)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using ticlopidine and call your doctor at once if you have a serious side effect such as:

nosebleed or other bleeding that will not stop;
black, bloody, or tarry stools;
coughing up blood or vomit that looks like coffee grounds;
chest pain or heavy feeling, pain spreading to the arm or shoulder,...
Read All Potential Side Effects for Ticlid »




TICLID (ticlopidine hydrochloride) is a platelet aggregation inhibitor. Chemically
it is 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno [3,2-c] pyridine hydrochloride.
The structural formula is:








Ticlopidine hydrochloride is a white crystalline solid. It is freely soluble
in water and self-buffers to a pH of 3.6. It also dissolves freely in methanol,
is sparingly soluble in methylene chloride and ethanol, slightly soluble in
acetone and insoluble in a buffer solution of pH 6.3. It has a molecular weight
of 300.25.
TICLID tablets for oral administration are provided as white, oval, film-coated,
blue-imprinted tablets containing 250 mg of ticlopidine hydrochloride. Each
tablet also contains citric acid, magnesium stearate, microcrystalline cellulose,
povidone, starch and stearic acid as inactive ingredients. The white film-coating
contains hydroxypropylmethyl cellulose, polyethylene glycol and titanium dioxide.
Each tablet is printed with blue ink, which includes FD&C Blue #1 aluminum
lake as the colorant. The tablets are identified with Ticlid on one side and
250 on the reverse side.Last reviewed on RxList: 6/10/2008




Ticlid Drug Description
TICLID®
(ticlopidine hydrochloride) Tablets

WARNING
TICLID can cause life-threatening hematological adverse reactions, including
neutropenia/agranulocytosis, thrombotic thrombocytopenic purpura (TTP) and aplastic anemia.
Neutropenia/Agranulocytosis: Among 2048 patients in clinical
trials in stroke patients, there were 50 cases (2.4%) of neutropenia (less than
1200 neutrophils/mm³), and the neutrophil count was below 450/mm³
in 17 of these patients (0.8% of the total population).
TTP: One case of thrombotic thrombocytopenic purpura was reported
during clinical trials in stroke patients. Based on postmarketing data, US physicians
reported about 100 cases between 1992 and 1997. Based on an estimated patient
exposure of 2 million to 4 million, and assuming an event reporting rate of
10% (the true rate is not known), the incidence of ticlopidine-associated TTP
may be as high as one case in every 2000 to 4000 patients exposed.
Aplastic Anemia: Aplastic anemia was not seen during clinical
trials in stroke patients, but US physicians reported about 50 cases between
1992 and 1998. Based on an estimated patient exposure of 2 million to 4 million,
and assuming an event reporting rate of 10% (the true rate is not known), the
incidence of ticlopidine-associated aplastic anemia may be as high as one case
in every 4000 to 8000 patients exposed.
Monitoring of Clinical and Hematologic Status: Severe hematological
adverse reactions may occur within a few days of the start of therapy. The incidence
of TTP peaks after about 3 to 4 weeks of therapy and neutropenia peaks at approximately
4 to 6 weeks. The incidence of aplastic anemia peaks after about 4 to 8 weeks
of therapy. The incidence of the hematologic adverse reactions declines thereafter.
Only a few cases of neutropenia, TTP, or aplastic anemia have arisen after more
than 3 months of therapy.
Hematological adverse reactions cannot be reliably predicted by any identified
demographic or clinical characteristics. During the first 3 months of treatment,
patients receiving TICLID must, therefore, be hematologically and clinically
monitored for evidence of neutropenia or TTP. If any such evidence is seen,
TICLID should be immediately discontinued.
The detection and treatment of ticlopidine-associated hematological adverse
reactions are further described under WARNINGS.

DRUG DESCRIPTION



What are the possible side effects of ticlopidine (Ticlid)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using ticlopidine and call your doctor at once if you have a serious side effect such as:

nosebleed or other bleeding that will not stop;
black, bloody, or tarry stools;
coughing up blood or vomit that looks like coffee grounds;
chest pain or heavy feeling, pain spreading to the arm or shoulder,...
Read All Potential Side Effects for Ticlid »




TICLID (ticlopidine hydrochloride) is a platelet aggregation inhibitor. Chemically
it is 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno [3,2-c] pyridine hydrochloride.
The structural formula is:








Ticlopidine hydrochloride is a white crystalline solid. It is freely soluble
in water and self-buffers to a pH of 3.6. It also dissolves freely in methanol,
is sparingly soluble in methylene chloride and ethanol, slightly soluble in
acetone and insoluble in a buffer solution of pH 6.3. It has a molecular weight
of 300.25.
TICLID tablets for oral administration are provided as white, oval, film-coated,
blue-imprinted tablets containing 250 mg of ticlopidine hydrochloride. Each
tablet also contains citric acid, magnesium stearate, microcrystalline cellulose,
povidone, starch and stearic acid as inactive ingredients. The white film-coating
contains hydroxypropylmethyl cellulose, polyethylene glycol and titanium dioxide.
Each tablet is printed with blue ink, which includes FD&C Blue #1 aluminum
lake as the colorant. The tablets are identified with Ticlid on one side and
250 on the reverse side.Last reviewed on RxList: 6/10/2008




Ticlid Drug Description
TICLID®
(ticlopidine hydrochloride) Tablets

WARNING
TICLID can cause life-threatening hematological adverse reactions, including
neutropenia/agranulocytosis, thrombotic thrombocytopenic purpura (TTP) and aplastic anemia.
Neutropenia/Agranulocytosis: Among 2048 patients in clinical
trials in stroke patients, there were 50 cases (2.4%) of neutropenia (less than
1200 neutrophils/mm³), and the neutrophil count was below 450/mm³
in 17 of these patients (0.8% of the total population).
TTP: One case of thrombotic thrombocytopenic purpura was reported
during clinical trials in stroke patients. Based on postmarketing data, US physicians
reported about 100 cases between 1992 and 1997. Based on an estimated patient
exposure of 2 million to 4 million, and assuming an event reporting rate of
10% (the true rate is not known), the incidence of ticlopidine-associated TTP
may be as high as one case in every 2000 to 4000 patients exposed.
Aplastic Anemia: Aplastic anemia was not seen during clinical
trials in stroke patients, but US physicians reported about 50 cases between
1992 and 1998. Based on an estimated patient exposure of 2 million to 4 million,
and assuming an event reporting rate of 10% (the true rate is not known), the
incidence of ticlopidine-associated aplastic anemia may be as high as one case
in every 4000 to 8000 patients exposed.
Monitoring of Clinical and Hematologic Status: Severe hematological
adverse reactions may occur within a few days of the start of therapy. The incidence
of TTP peaks after about 3 to 4 weeks of therapy and neutropenia peaks at approximately
4 to 6 weeks. The incidence of aplastic anemia peaks after about 4 to 8 weeks
of therapy. The incidence of the hematologic adverse reactions declines thereafter.
Only a few cases of neutropenia, TTP, or aplastic anemia have arisen after more
than 3 months of therapy.
Hematological adverse reactions cannot be reliably predicted by any identified
demographic or clinical characteristics. During the first 3 months of treatment,
patients receiving TICLID must, therefore, be hematologically and clinically
monitored for evidence of neutropenia or TTP. If any such evidence is seen,
TICLID should be immediately discontinued.
The detection and treatment of ticlopidine-associated hematological adverse
reactions are further described under WARNINGS.

DRUG DESCRIPTION



What are the possible side effects of ticlopidine (Ticlid)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using ticlopidine and call your doctor at once if you have a serious side effect such as:

nosebleed or other bleeding that will not stop;
black, bloody, or tarry stools;
coughing up blood or vomit that looks like coffee grounds;
chest pain or heavy feeling, pain spreading to the arm or shoulder,...
Read All Potential Side Effects for Ticlid »




TICLID (ticlopidine hydrochloride) is a platelet aggregation inhibitor. Chemically
it is 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno [3,2-c] pyridine hydrochloride.
The structural formula is:








Ticlopidine hydrochloride is a white crystalline solid. It is freely soluble
in water and self-buffers to a pH of 3.6. It also dissolves freely in methanol,
is sparingly soluble in methylene chloride and ethanol, slightly soluble in
acetone and insoluble in a buffer solution of pH 6.3. It has a molecular weight
of 300.25.
TICLID tablets for oral administration are provided as white, oval, film-coated,
blue-imprinted tablets containing 250 mg of ticlopidine hydrochloride. Each
tablet also contains citric acid, magnesium stearate, microcrystalline cellulose,
povidone, starch and stearic acid as inactive ingredients. The white film-coating
contains hydroxypropylmethyl cellulose, polyethylene glycol and titanium dioxide.
Each tablet is printed with blue ink, which includes FD&C Blue #1 aluminum
lake as the colorant. The tablets are identified with Ticlid on one side and
250 on the reverse side.Last reviewed on RxList: 6/10/2008





Other reviews about Ticlid on wordpress

Buy Ticlid Online Order Cheap Ticlid Generic Purchase Discount Without Prescription
  by worlddnews
FOLLOW THIS LINK FOR ENTER TO TRUSTED & REPUTABLE ONLINE DRUGSTORE WHERE YOU CAN GET ALL QUALIFIED INFORMATION ABOUT Ticlid ONLINE     There is also the type to absorb the […]


So...what are the treatments?
  by physio123
At this point, you're probably wondering if there's any hope for patients suffering from a heart attack or stroke. A common question is if you should give them […]


Alesse Laser hair loss
  by taffyrichardson
The PMN half-life was 49.2 h. Plasma samples were sleeping disease stomach insomnia indigestion pills collected after p.o. Peripheral blood PMN and bronchoalveolar lavage fluid and alveolar cells […]


Tramadol Does tramadol cause weight gain
  by silviawhowardi
It is clear that the majority of newborns acquire their infection by contact with infected genital secretions during delivery from an asymptomatic mother who acquired a first episode […]


Dr Kelly Sennholz: FDA Warns of Medication Danger
  by Dr. Kelly Sennholz
Several commonly prescribed drugs, such as Nexium and Prilosec, have been identified by the FDA as decreasing the effectiveness of the blood thinning drug, Plavix.  This drug is […]


Avoid Coadministration of Clopidogrel [Plavix] and Omeprazole [Prilosec] or Esomeprazole [Nexium]
  by thassodotcom
November 17, 2009 - Today, the US Food and Drug Administration (FDA) informed on new data showing that the proton pump inhibitor (PPI) Omeprazole [Prilosec] or [Prilosec OTC] […]


FDA issues Plavix/Prilosec Combination Warning
  by themathewslawfirm
FDA Announces New Warning on Plavix: Avoid Use with Prilosec/Prilosec OTC Patients should avoid using the stomach acid reducer Prilosec/Prilosec OTC (omeprazole) with the anti-clotting drug Plavix (clopidogrel), the U.S. Food […]


Don’t take Plavix with acid reducers
  by Health News
The Food and Drug Administration warns that acid-reflux drugs Prilosec and Nexium should not be taken with blood-thinner Plavix. Plavix’s label cautions against the use of the heartburn drugs, […]


Don’t mix Clopidogrel with Omeprazole!
  by gamtet
The FDA has issued a public health advisory warning patients and physicians that concomitant use of clopidogrel (Plavix) and omeprazole (Omez) blunts the antiplatelet effect of clopidogrel, thus […]


Alternative & Natural Varicose Vein Treatment
  by gpsportabletracking
http://static.pixelpipe.com/1d929092-43d5-4fc4-91e1-de163d912324.wmv http://www.varicoseveincures.com/ Laser treatment and sclerotherapy are just two of the options if you want to undergo Varicose vein treatment. If these do not suit you, there are alternative forms […]



Other reviews about Ticlid on web:

Learn about the prescription medication Ticlid (Ticlopidine Hcl), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Ticlid (Ticlopidine Hcl) Drug Information: Uses, Side Effects ...


Accurate, FDA approved Ticlid information for healthcare professionals and patients - brought to you by Drugs.com. Ticlid Official FDA information, side effects and uses.


Find patient medical information for Ticlid Oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings. Ticlid Oral : Uses, Side Effects, Interactions, Pictures, Warnings ...


Ticlopidine (trade name Ticlid) is an antiplatelet drug in the thienopyridine family. Like clopidogrel, it is an adenosine diphosphate (ADP) receptor inhibitor. Ticlopidine - Wikipedia, the free encyclopedia


All about Ticlid. View complete and up to date Ticlid information - part of the Drugs.com trusted medication database. Ticlid Facts and Comparisons at Drugs.com


Information on ticlopidine (Ticlid) a drug prescribed for the prevention of strokes or TIAs (mini-strokes) to prevent blood clots in stents placed in the heart. Off label uses are ... Ticlopidine (Ticlid) Drug Information by MedicineNet.com


Consumer information about the medication TICLOPIDINE - ORAL (Ticlid), includes side effects, drug interactions, recommended dosages, and storage information. Read more about ... TICLOPIDINE - ORAL (Ticlid) side effects, medical uses, and drug ...


Ti·clid (t kl d) A trademark for the drug ticlopidine hydrochloride. ticlopidine hydrochloride. Ticlid. Pharmacologic class: Platelet aggregation inhibitor Ticlid - definition of Ticlid in the Medical dictionary - by the ...


What is Ticlid (Ticlopidine)? Ticlopidine keeps the platelets in your blood from coagulating (clotting) to prevent unwanted blood clots that can occur with certain heart or ... Ticlid - Drugs & Treatments - Revolution Health


buy rx ticlid medication, prescription 250mg ticlid,buy ticlid prescription, platelet aggregation inhibitor from TruMedCanada in B.C. Canada. Rx Ticlid Medication - Prescription 250mg Ticlid, Buy Ticlid ...





Featured Reviews

Reviews Afluria

Afluria Drug Description AFLURIA® Influenza Virus Vaccine Suspension for Intramuscular Injection 2007-2008 Formula DRUG DESCRIPTION What are the possible side effects of influenza virus injectable vaccine? Influenza virus...
Read More  |  Review This
Reviews Tirosint

Tirosint Drug Description Tirosint™ (levothyroxine sodium) Capsule DRUG DESCRIPTION TIROSINT™ (levothyroxine sodium) capsules are soft gelatin capsules to be orally administered, which contain synthetic L-3,3',5,5'-tetraiodothyronin...
Read More  |  Review This
Reviews Glipizide

Glucotrol Drug Description GLUCOTROL® (glipizide) Tablets for Oral Use DRUG DESCRIPTION What are the possible side effects of glipizide (Glucotrol, Glucotrol XL)? Stop taking glipizide and seek emergency medical attention if...
Read More  |  Review This
Reviews Catapres-TTS

Catapres-TTS Drug Description Catapres-TTS (clonidine) Catapres-TTS -1 Catapres-TTS -2 Catapres-TTS -3 Transdermal Therapeutic System Programmed delivery in vivo of 0.1, 0.2, or 0.3 mg clonidine per day, for one week. DRUG...
Read More  |  Review This
Reviews Edex

Edex Drug Description Edex® (alprostadil) for Injection For Intracavernous Use Only Sterile Powder and Diluent (sterile 0.9% sodium chloride) in Cartridges DRUG DESCRIPTION What are the possible side effects of alprostadil...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....